Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells

Nayanendu Saha,Kai Xu,Zhongyu Zhu,Dorothea Robev,Teja Kalidindi,Yan Xu,Juha Himanen,Elisa de Stanchina,Naga Vara Kishore Pillarsetty,Dimiter S Dimitrov,Dimitar B Nikolov

Translational Oncology（2022）

引用 4|浏览31

暂无评分

摘要

•A novel anti-ADAM17 monoclonal antibody, D8P1C1, has been developed.•D8P1C1 inhibits the proteolysis of peptide substrates by ADAM17.•D8P1C1 inhibits the proliferation of cancer cells and tumor growth inhibition in vivo.•D8P1C1 preferentially recognizes ADAM17 on cancer cells.•Negative stain EM analysis reveals that D8P1C1 binds to the ADAM17 protease domain.

查看译文

关键词

ADAM17,Monoclonal antibody,EGFR signaling,Cancer therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要